Claritus Pharmaceuticals Inc. (CLAZF)

[TheShadow]

“As previously discussed, the business strategy we are pursuing for our GVHD products is to out-license the commercial rights for these products after we have completed the ongoing Phase 2 study in prevention of GVHD,” stated Robert Farrell, President and CEO of Kalytera. “Consistent with this strategy, and based on the fact that we have already received unsolicited inquiries regarding the rights to these products, we have chosen to engage Echelon to determine the current risk adjusted value of these products, and to assist us in managing the process for identifying the optimum corporate partner or partners who may assist with some or all further costs for development of these products, such as the costs for Phase 3 clinical testing. Echelon will also assist Kalytera in evaluating any consideration that may be received by Kalytera for the commercial rights to its GVHD products, such as up-front license fees, and/or milestone payments and royalties.”

https://kalytera.co/news/kalytera-announces-engagement-of-echelon-wealth-partners-to-assist-with-review-of-potential-out-license-opportunities-for-commercial-rights-to-gvhd-products/